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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease of the lungs that is
currently the fourth leading cause of death worldwide. Genetic factors account for only a small amount of
COPD risk, but epigenetic mechanisms, including DNA methylation, have the potential to mediate the
interactions between an individual’s genetics and environmental exposure. DNA methylation is highly cell
type-specific, and individual cell type studies of DNA methylation in COPD are sparse. Fibroblasts are present
within the airway and parenchyma of the lung and contribute to the aberrant deposition of extracellular
matrix in COPD. No assessment or comparison of genome-wide DNA methylation profiles in the airway and
parenchymal fibroblasts from individuals with and without COPD has been undertaken. These data provide
valuable insight into the molecular mechanisms contributing to COPD and the differing pathologies of small
airways disease and emphysema in COPD.
Methods: Genome-wide DNA methylation was evaluated at over 485,000 CpG sites using the Illumina Infinium
HumanMethylation450 BeadChip array in the airway (non-COPD n = 8, COPD n = 7) and parenchymal fibroblasts
(non-COPD n = 17, COPD n = 29) isolated from individuals with and without COPD. Targeted gene expression was
assessed by qPCR in matched RNA samples.
Results: Differentially methylated DNA regions were identified between cells isolated from individuals with and
without COPD in both airway and parenchymal fibroblasts. Only in parenchymal fibroblasts was differential DNA
methylation associated with differential gene expression. A second analysis of differential DNA methylation
variability identified 359 individual differentially variable CpG sites in parenchymal fibroblasts. No differentially
variable CpG sites were identified in the airway fibroblasts. Five differentially variable-methylated CpG sites,
associated with three genes, were subsequently assessed for gene expression differences. Two genes (OAT and
GRIK2) displayed significantly increased gene expression in cells isolated from individuals with COPD.
Conclusions: Differential and variable DNA methylation was associated with COPD status in the parenchymal
fibroblasts but not airway fibroblasts. Aberrant DNA methylation was associated with altered gene expression
imparting biological function to DNA methylation changes. Changes in DNA methylation are therefore implicated
in the molecular mechanisms underlying COPD pathogenesis and may represent novel therapeutic targets.
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Background
Chronic obstructive pulmonary disease (COPD) affects
300 million people worldwide, is currently the fourth
leading cause of death in the world, and is expected to
become the third leading cause of mortality worldwide
by 2020 [1]. Clinically defined by airflow obstruction that
is not reversible, COPD is a heterogeneous disease
within the lung involving parenchymal lung destruction
resulting in loss of elastic recoil (emphysema) and small
airway disease [2, 3]. COPD is caused by exposure to
noxious particles or gases that are predominantly intro-
duced into the lung by cigarette smoking, or other expo-
sures such as biomass fuels. The irreversible airflow
obstruction is not reversed by cigarette smoking cessa-
tion, and to date, there are no therapies that can modify
disease activity or progression. A better understanding
of the molecular processes underlying the pathology of
COPD is crucial to the design of novel therapeutics [4].
Genome-wide genetic association studies (GWAS)
have identified four susceptibility loci for COPD that are
associated with smoking behavior and have been well
replicated [5–12], but each variant explains only a small
amount of the risk for COPD [1]. It is therefore sug-
gested that epigenetic processes may contribute to
COPD risk by mediating the link between genetic vari-
ation and environmental exposure [1]. DNA methylation
is a heritable, tissue-specific epigenetic modification to
DNA that regulates gene expression [4]. It is fundamen-
tal to normal development and is known to play a cru-
cial role in a number of chronic inflammatory diseases
including cancer and aging [13]. The reversibility of
DNA methylation makes it an attractive target for drug
design. There is strong evidence of dysregulated DNA
methylation in association with COPD [1, 13]. For ex-
ample, 349 CpG sites are differentially methylated in
white blood cells of individuals with COPD compared to
individuals without COPD [1]. Furthermore, several
studies have assessed aberrant DNA methylation in the
whole lung tissue with varying levels of significance de-
pending on sample number [13], integration with gene
expression [2], and integration with GWAS results [14].
However, in terms of understanding molecular processes
in COPD, these studies are limited by two factors: either
they were performed in blood, having relevance as blood-
based biomarkers of disease but with limited translation
to lung pathology, or they were performed in the whole
lung tissue where cell type-specific methylation profiles
will likely have masked disease relevant alterations. Fur-
ther, mixed cell populations in whole tissue complicate
subsequent cell type-specific mechanistic studies to
understand disease biology. An exception is the identifica-
tion of 1260 CpGs differentially methylated in small air-
way epithelial cells between cells isolated from former
smokers with and without COPD, which was associated
with altered expression of 471 genes [4]. This study
strongly suggests that cell type-specific alterations to
DNA methylation exist in association with COPD status.
In the present study, we focused on DNA methylation
in the lung fibroblasts. Fibroblasts are mesenchymal cells
found in the stroma of many tissues and in the adventitia
of the vasculature, airways, and parenchyma of adult lungs
[15]. They are crucial for stem cell maintenance, lung re-
pair, and the homeostasis of the extracellular matrix. The
airway and parenchymal fibroblasts from COPD patients
differ in physiological extracellular matrix (ECM) produc-
tion [16–18], response to TGFβ [16], response to steroids
[16], and proliferation rate [17]. Fibroblasts isolated from
the lung parenchyma of individuals with COPD are less
contractile [19, 20], less active to chemoattractant migra-
tion [19], and express and secrete increased levels of in-
flammatory cytokines CXCL8 and IL-6 [21] compared to
parenchymal fibroblasts from individuals without COPD,
suggesting they have diminished capacity to mediate re-
pair responses potentially contributing to emphysema de-
velopment and an enhanced pro-inflammatory profile.
Fibroblasts isolated from the intrapulmonary airways
within the lungs of COPD patients have been shown to
have increased extracellular matrix deposition [16, 17].
The different pathophysiology of emphysema and small
airway disease in COPD highlights the necessity to study
fibroblasts from these two locations distinctly and in com-
parison to fully understand the molecular mechanisms
underlying COPD pathogenesis.
In this study, we aimed to identify differences in
genome-wide DNA methylation profiles and their asso-
ciations with differences in gene expression, between the
airway and parenchymal fibroblasts isolated from indi-
viduals with and without COPD, to further understand
in a cell-specific manner the molecular mechanisms
underlying the pathogenesis of COPD. We found that
parenchymal fibroblasts, but not airway fibroblasts, had
DNA methylation associated alterations in gene expres-
sion, implicating DNA methylation as a molecular
mechanism underlying parenchymal dysfunction in
COPD. These data provide novel evidence that the air-
way and parenchymal fibroblasts are epigenetically dif-
ferent in COPD and suggest that alterations to DNA
methylation contribute to COPD pathogenesis.
Methods
Isolation and culture of airway and parenchymal
fibroblasts
Primary cultures of airway and parenchymal fibroblasts
from patients with and without COPD (airway: non-COPD
n = 8, COPD n = 7; parenchymal: non-COPD n = 17,
COPD n = 29, detailed demographics provided in the “Re-
sults” section) (defined by the Global Initiative for Chronic
Obstructive Pulmonary Disease (GOLD) guidelines using
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spirometry) were established from lung biopsies or intra-
pulmonary airways and parenchymal lung tissue obtained
from lung cancer resections (from disease-free areas) sur-
geries, donor lungs, and explant lungs from individuals
with COPD undergoing lung transplantation. Airway and
parenchymal fibroblasts were derived using the outgrowth
techniques as previously described [22, 23]. Briefly, 2-mm2
tissue explants were placed in 6-well tissue culture plates
with DMEM (Sigma) containing 10% fetal bovine serum
(GIBCO, Life Technologies), penicillin (100 U/ml), strepto-
mycin (100 μg/ml), and l-glutamine (4 mM) in a 5% CO2-
humidified incubator. Media were replaced regularly until
cellular outgrowth reached confluence. Tissue pieces were
removed and destroyed, and cells were harvested using
trypsin/EDTA solution (Sigma). All samples were gener-
ated from cells at passage 4 except a single airway fibro-
blast non-COPD donor that was collected at passage 3.
Cells at the required passage were grown to confluence in
6-well plates and serum starved for 24 h prior to lysis for
DNA and RNA isolation. The tissue was obtained, and
cells were extracted with the approval of each of the re-
search ethics boards for each of the academic institutions
involved: Newcastle University (NRES Committee: New-
castle and North Tyneside 1 ref:11/NE/0291), McMaster
University (Hamilton Integrated Research Ethics Board
Ref:00–1839), University of British Columbia (Providence
Health Care Research Ethics Board Ref:H13-02173), Uni-
versity of Nottingham (East Midlands Research Ethics
Committee ref: 08/H0407/1), and University Medical Cen-
ter Groningen. This study was conducted according to the
national ethical and professional guidelines on the use hu-
man body material (“Code of conduct; Dutch federation of
biomedical scientific societies”; https://www.federa.org/
codes-conduct) and the Research Code of the University
Medical Center Groningen (https://www.umcg.nl/EN/
Research/Researchers/General/ResearchCode/Paginas/
default.aspx). The demographics of the subject lung fibro-
blasts assessed are given in Table 1.
DNA and RNA isolation
DNA and RNA were simultaneously isolated from each
sample using the AllPrep DNA/RNA Mini Kit (Qiagen)
as per manufacturer’s instructions and assessed for qual-
ity and quantity using a NanoDrop™ 8000 Spectropho-
tometer (Thermo Fisher Scientific).
Bisulfite conversion and DNA methylation arrays
Seven hundred fifty nanograms of purified genomic
DNA was bisulfite converted using the EZ DNA
Methylation Kit (Zymo Research) as per the manufac-
turer’s instructions. Specific incubation conditions for
the Illumina Infinium Methylation Assay were used as
per the manufacturer’s protocol Appendix. Samples
were eluted in 12 μl. Bisulfite-converted DNA was
assessed for concentration and quality using a
NanoDrop™ 8000 Spectrophotometer (Thermo Fisher
Scientific), and 160 ng of the conversion product was
used for genome-wide DNA methylation quantifica-
tion at over 485,000 CpG sites using the Illumina
Infinium HumanMethylation450 BeadChip array, ac-
cording to the manufacturer’s protocols.
Data quality control and normalization
IDAT files produced by GenomeStudio were imported
into the R statistical software (version 3.2.1) using the
minfi package (v. 1.14.0) [24]. The 65 known quality
control SNP probes were used to cluster all samples to
detect anomalies within the samples from the same
donor. Probes were excluded from further analysis ac-
cording to several criteria: first, 1402 probes were found
Table 1 Donor demographics
Airway fibroblasts Parenchymal fibroblasts
Non-COPD COPD Non-COPD vs
COPD p value
Non-COPD COPD Non-COPD vs
COPD p value
Airway vs parenchymal
COPD p value
N 8 7 17 29
Gender
(M/F)
2/6 6/1 0.0187 9/8 18/11 0.544 0.2336
Age
Mean (SD)
63.36 (10.06) 68 (5.63) 0.3097 65.06 (11.31) 65.1 (9.60) 0.9994 0.4489
Pack-years
Mean (SD)
21.6 (18.89) 53.4 (29.84) 0.0221 31.8 (25.52) 39.8 (19.94) 0.3345 0.1798
FEV1%
Mean (SD)
100.8 (11) 69.7 (18.5) 0.0046 95.6 (17.2) 47.8 (26.3) < 0.0001 0.0457
FEV1/FVC %
Mean (SD)
77.42 (7.2) 59.8 (12) 0.0035 76.6 (6.4) 44.8 (15.5) < 0.0001 0.0182
GOLD stage NA 2× GS1, 3×
GS2, 2× GS3
NA NA 3× GS1, 10× GS2,
3× GS3, 13× GS4
NA NA
M male, F female, COPD chronic obstructive pulmonary disease, SD standard deviation, FEV forced expiratory volume, FVC forced vital capacity, NA not applicable
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to have either a detection p value < 0.05 in at least 1% of
samples or had less than three bead count in at least 5%
of samples; second, the 65 SNP probes; third, 59,593
probes were found to be cross-hybridized to other parts
of the genome, known to be polymorphic at the CpG or
examine single nucleotide polymorphisms [25]; finally,
9925 sites on the X chromosome or the Y chromosome.
Four hundred fourteen thousand five hundred ninety-
two probes remained for analysis.
Filtered probes were normalized using the funtoo-
Norm algorithm [26], which extends the funNorm
procedure [27] and is purported to correct for un-
wanted variation while preserving important differ-
ences in methylation patterns between different cell
types. We employed the normalization option of prin-
cipal components regression with five principal com-
ponents. Two values of DNA methylation were used,
beta values (β values) and M values. β values are the
ratio of all methylated probe intensities over total sig-
nal intensities (methylated and unmethylated) and
have a range from 0 to 1. They approximately repre-
sent percent methylation. M values are the log trans-
formation of β values and are more statistically
robust [28]. All statistical analyses were performed
using M values, while β values were used for
visualization and interpretability purposes. Principal
component analysis was performed for quality control
of the M values.
Differential DNA methylation analysis
All statistical analyses were performed using R statistical
software (version 3.2.1). Probes with DNA methylation
levels significantly different between non-COPD donors
and COPD donors in the airway and parenchymal fibro-
blasts separately were identified using the limma pack-
age using multivariable linear regression on M values
adjusting for covariates [29] followed by control of the p
values of the main effect coefficient for false discovery
rate via the Benjamini-Hochberg procedure [30] across
all CpG sites on the array. For airway fibroblasts, bio-
logical sex and smoking pack-years were included as co-
variates. As no independently significant sites were
identified using limma, we looked at aggregated sites to
identify differentially methylated regions (DMRs) using
the DMRcate package in R [31], which uses Gaussian
kernel smoothing to find patterns of differential methy-
lation, agnostic to genomic annotation. We used the au-
thors’ recommended bandwidth (λ) of 1000 base pairs
and scaling factor (C) of 2. For airway fibroblasts, we
used a nominal p value cutoff of p < 0.005, which yielded
an analysis of 3432 CpG sites. For the parenchymal
fibroblast analysis, all donors were sex- and pack-years
matched so a more lenient nominal p value cutoff of p <
0.01 was used, which yielded an analysis of 2837 CpG
sites.
Variable DNA methylation analysis
Variable DNA methylation analysis was performed using
the iEVORA algorithm in R [32] and the recommended
q value cutoff for variably methylated points (DVPs) of
p < 0.001.
Reverse transcription and qPCR
0.5 μg of RNA was reverse transcribed using SuperScript
IV (Invitrogen), as per the manufacturer’s instructions.
The resulting 20 μl cDNA samples were diluted to a
total volume of 200 μl using nuclease-free water. cDNA
was amplified using PerfeCTa SYBR Green FastMix
(Quanta bio), with 2 μl template and 200 nM primers in
a 10-μl reaction using a Stratagene Mx3000P/3005P sys-
tem. Thermal cycler conditions included incubation at
95 °C for 10 min, followed by 40 cycles of 95 °C for 10 s,
60 °C for 30 s, and 72 °C for 20 s. Data were collected in
MxPro; a single product was confirmed by melt curve
analysis, and Ct values were exported to Excel for ana-
lysis. Expression was expressed by the ΔΔCt method
relative to β2-microglobulin (β2M) Ct and mean non-
COPD target/β2M ΔCt. Each cDNA was run in triplicate
for both the target gene and housekeeping gene. The
mean of the triplicate Cts were taken and the ΔCt be-
tween target and housekeeping gene calculated. The
mean ΔCt for non-COPD samples was calculated and
ΔΔCts were calculated relative to the mean non-COPD
ΔCt. Primer sequences are as follows: β2-microglobulin,
forward 5′-AATCCAAATGCGGCATCT-3′, reverse
5′-GAGTATGCCTGCCGTGTG-3′; TMEM44, for-
ward 5′-GGCACTGGACCTCGCTATTA-3′, reverse
5′-CAGGCTCGATGGTCAGCTC-3′; NXN, forward
5′-AGACTCTGTTTGGGAGCACG-3′, reverse 5′-TGAC
TTTGCGAAAGCCATGC-3′; HLX, forward 5′-CGTTT
CCAGGTCCCTATGCT-3′, reverse 5′-CGGTTCTGGAA
CCACACCTT-3′; SPON2, forward 5′-TCCCACGTGG
TTGCAGATAC-3′, reverse 5′-TTCCGAAACCGCCCCA
TTTA-3′; TRPV3, forward 5′-GTGGCCTGCCTGGCG-
3′, reverse 5′-GCTTTCATGGCTGGTGAGGT-3′; OAT,
forward 5′-CGCTGTCAGATCTGTGGTTT-3′, reverse
5′-ACTCCGCGACTAAGTACA-3′; and GRIK2, forward
5′-CATGCAGCAAGGTTCTGAGC-3′, reverse 5′-CACT
GTCAGAAAGGCGGCTA.
Bisulfite PCR-pyrosequencing
Bisulfite PCR-pyrosequencing was used to validate differ-
ences in DNA methylation cg16009558 (GRIK2). Bisulfite
PCR-pyrosequencing assays were designed with PyroMark
Assay Design 2.0 (Qiagen). The regions of interest were
amplified by PCR using the HotstarTaq DNA polymerase
kit (Qiagen) as follows: 15 min at 95 °C (to activate the Taq
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polymerase), 45 cycles of 95 °C for 30s, 58 °C for 30s, and
72 °C for 30s, and a 5 min 72 °C extension step. For pyrose-
quencing, single-stranded DNA was prepared from the
PCR product with the Pyromark™ Vacuum Prep Worksta-
tion (Qiagen), and sequencing was performed using se-
quencing primers on a Pyromark™ Q24 pyrosequencer
(Qiagen). The quantitative levels of methylation for each
CpG dinucleotide were calculated with Pyromark Q24 soft-
ware (Qiagen). Primer sequences were forward
biotinylated-5′-ATTTTAGTTTTTTTTATTTAATTTTG
GTTT-3′, reverse 5′-CAAAAATTTTACCAAACCCTATT
CTACT-3′, sequencing 5′-ACACTACTACACAACTTCT
AA-3′. Samples were the same bisulfite converted samples
used on the array. COPD versus non-COPD donors were
demographically matched.
Results
Demographic data
Genome-wide DNA methylation data analysis was per-
formed using airway fibroblasts from 7 patients with
COPD and 8 non-COPD controls and parenchymal fi-
broblasts from 29 patients with COPD and 17 non-
COPD controls (Table 1). Due to the nature of the surgi-
cal procedures from which the lung tissue was taken,
there were no paired airway and parenchymal cells from
the same donor in the current dataset. There were no
significant differences between COPD and non-COPD
parenchymal fibroblast samples based on their age, sex,
or pack-years smoking history. There were significant
differences between COPD and non-COPD airway fibro-
blast samples based on their sex and pack-years smoking
history, and these were included as covariates in the stat-
istical models. There was also a significant difference in
COPD severity between the airway and parenchymal fi-
broblasts as defined by FEV1% and FEV1/FVC%.
Differentially methylated DNA regions were associated
with COPD status in the airway and parenchymal
fibroblasts
To understand whether differential DNA methylation was
associated with COPD in either airway or parenchymal fi-
broblasts, we assessed genomic DNA methylation using the
Illumina Infinium HumanMethylation450 BeadChip. After
quality control, 414,592 probes remained for analysis.
We looked to identify individually differentially methyl-
ated CpG sites with linear regression, with COPD status
as the variable of interest. Linear modeling did not identify
any independently significant sites, after adjusting for mul-
tiple tests, in either airway or parenchymal fibroblasts.
Subsequently, we assessed differential methylation on ag-
gregated sites using the regional DNA methylation R
package DMRcate [31], including all CpGs specified by a
nominal p value limit of 0.005 for airway fibroblasts (3432
CpG sites) and a more lenient 0.01 for parenchymal
fibroblasts (2837 CpG sites). In airway fibroblasts, 887 dif-
ferentially methylated regions were identified in COPD
that contained at least three CpG sites. Six hundred fifty-
two of these regions were annotated to a known gene, and
35 had a maximum difference in DNA methylation (i.e., at
least one probe displayed a mean difference in methyla-
tion) of 20% (Δβ = 0.2) (Fig. 1a and Additional file 1: Table
S1). Twelve of these regions had increased DNA methyla-
tion associated with COPD, while in 23 regions, DNA
methylation was decreased with COPD status. The five re-
gions with the largest maximum difference in DNA
methylation were associated with the genes: TMEM44
(Fig. 1b, max Δβ = 0.26), RPH3AL (Fig. 1c, max Δβ = 0.39),
HLA-DP1 (Fig. 1d, max Δβ = 0.31), WNT3A (Fig. 1e, max
Δβ = 0.27), and HLA-DRB5 (Fig. 1f, max Δβ = 0.28). The
regions associated with TMEM44, RPH3AL, and HLA-
DRB5 did not display a consistent hypomethylation or
hypermethylation association with COPD across all of the
region CpGs. However, the regions associated with HLA-
DPB1 andWNT3 displayed consistent hypomethylation in
association with COPD status.
In parenchymal fibroblasts, we identified 44 DNA differ-
entially methylated regions containing at least three CpG
sites, 39 of which were annotated to a gene but only three
with a maximum Δβ of 0.2 (Fig. 2a and Additional file 2:
Table S2). Two regions associated with genes HLX (Fig. 2b)
and LOC100130872-SPON2 (Fig. 2c) were hypermethy-
lated with COPD status while a single region associated
with NXN was hypomethylated (Fig. 2d).
Differentially methylated DNA regions were associated
with changes in steady-state gene expression with COPD
status in parenchymal but not airway fibroblasts
To infer a biological significance of the differentially
methylated DNA regions on cell function in COPD, we
performed targeted gene expression analysis for the five
airway fibroblast regions with the largest maximum differ-
ence in DNA methylation and the three parenchymal fibro-
blasts regions. In airway fibroblasts, gene expression of
RPH3AL, HLA-DP1, WNT3A, and HLADRB5 was not de-
tectable. Primer functionality was confirmed by positive
amplification in cDNA from the whole lung samples (data
not shown). TMEM44 expression was detected but showed
no difference in expression between cells isolated from in-
dividuals with COPD versus those without COPD (Fig. 3a).
In parenchymal fibroblasts, all transcripts except
LOC100130872 were detectable. NXN showed no differ-
ence in expression between cells isolated from individuals
with COPD versus those without COPD (Fig. 3b). However,
both HLX (Fig. 3c, p value = 0.0011 unpaired t test) and
SPON2 (Fig. 3d, p value = 0.0016 unpaired t test) showed a
significant decrease in gene expression in cells isolated from
individuals with COPD versus those without COPD.
Clifford et al. Clinical Epigenetics  (2018) 10:32 Page 5 of 14
Variable DNA methylation is more strongly associated
with differential steady-state gene expression with COPD
status in parenchymal fibroblasts
Identifying differentially methylated CpG sites refers to
comparing mean DNA methylation between cases and
controls and is a standard analytical approach for identi-
fying disease-associated CpG sites. Recently, the import-
ance of increased DNA methylation variability has been
identified as a predictor of progression to neoplasia in
precursor cervical cancer legions [32] and has been asso-
ciated with type 1 diabetes in three immune effector cell
types [33]. Differentially variable CpG positions (DVPs)
can identify larger differences in CpG methylation al-
though in a smaller number of the samples [33].
As such, we assessed DNA methylation variability
using the iEVORA algorithm in R and the association
with COPD status in the airway and parenchymal fibro-
blasts. Using the recommended p value cutoff of 0.001,
no DVPs were identified in airway fibroblasts; however,
359 CpG sites were identified in parenchymal fibro-
blasts. Three hundred twenty-seven of these CpG sites
displayed greater variability (as assessed by a larger
a
b c
d
f
e
Fig. 1 Regional DNA methylation differs in airway fibroblasts isolated from donors with COPD versus non-COPD. a Summary of regional DNA
methylation differences between DNA isolated from donors with and without COPD. Circle size represents the number of probes per regions.
Orange = hypomethylated in COPD samples, blue = hypermethylated in COPD. b–f Detailed plots of the five regions with the greatest maximum
difference in DNA methylation between DNA isolated from donors with and without COPD
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standard deviation) in cell samples isolated from individ-
uals with COPD, 32 CpGs displayed greater variability in
non-COPD cells (Additional file 3: Figure S1a). The ma-
jority of DVPs were located within CpG islands, but the
distribution of location did not differ from the distribu-
tion of the full analysis probes set (Additional file 3: Fig-
ure S1b). Two hundred eighty-seven DVPs were gene
annotated, with 45 within 200 bp of a transcription start
site. We hypothesized that if the variation in CpG
methylation is contributing to dysfunctional gene ex-
pression in parenchymal fibroblasts in COPD, the CpG
sites would have relatively stable methylation (low vari-
ation) in cells isolated from individuals without COPD
and become more variable in cells isolated from individ-
uals with COPD. We therefore followed these criteria to
identify CpG sites most likely to be associated with dys-
functional gene expression: (1) CpGs with greater vari-
ation in cells isolated from individuals with COPD than
those without, n = 327; (2) CpGs with stable methylation
in cells from individuals without COPD as repre-
sented by a standard deviation across samples of <
0.03, n = 261; (3) CpGs with the greatest variability in cells
isolated from individuals with COPD, as represented by a
standard deviation > 0.1, n = 40; and (4) CpGs are within
200 bp of a transcription start site and potentially most
likely to modulate gene expression, n = 5. These remaining
a
b c
d
Fig. 2 Regional DNA methylation differs in parenchymal fibroblasts isolated from donors with COPD versus non-COPD. a Summary of regional
DNA methylation differences between DNA isolated from donors with and without COPD. Circle size represents the number of probes per
regions. Orange = hypomethylated in COPD samples, blue = hypermethylated in COPD. b–d Detailed plots of the three regions with a maximum
difference in DNA methylation between DNA isolated from donors with and without COPD of greater than 20% (beta value difference of 0.2)
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five CpG sites were annotated to the promoters of three
separate genes, TRPV3 (cg11475555, Fig. 4a), OAT
(cg02065151, Fig. 4b), GRIK2 (cg24753760, Fig. 4c;
cg16009558, Fig. 4d; and cg06247406, Fig. 4e). GRIK2
CpG cg16009558 was validated by pyrosequencing and
confirmed a significant correlation between pyrosequenc-
ing and array methylation (r = 0.6329, p value = < 0.001,
Fig. 4f).
We assessed the potential biological relevance of variable
DNA methylation at these sites by measuring steady-state
gene expression. While TRPV3 showed a non-significant
trend toward increased gene expression in cells isolated
from individuals with COPD (p = 0.0618 Welch’s t test,
Fig. 5a), both OAT (p = 0.0109 Welch’s t test, Fig. 5b) and
GRIK2 (p = 0.0358 Welch’s t test, Fig. 5c) showed a signifi-
cant increase in gene expression in cells isolated from indi-
viduals with COPD versus those without COPD. In
particular, in cells from four COPD donors, GRIK2 showed
a greater than 20-fold increase in gene expression. Subse-
quently, we asked, for these specific genes, whether
expression correlated with DNA methylation in parenchy-
mal fibroblasts isolated from individuals with COPD. OAT
expression did not correlate with methylation of
cg02065151 (Fig. 6a). Although TRPV3 showed a non-
significant trend toward increased gene expression between
parenchymal fibroblasts isolated from individuals with and
without COPD, TRPV3 expression did correlate with
cg11475555 methylation, suggesting DNA methylation
may play a role in regulating TRPV3 expression (Fig. 6b).
The expression of GRIK2 strongly correlated with methyla-
tion of all three GRIK2 CpGs determined as DVPs in
COPD (cg24753760, Fig. 6c; cg06247406, Fig. 6d;
cg16009558, Fig. 6e), highly suggestive of aberrant GRIK2
CpG methylation leading to increased GRIK2 expression in
COPD parenchymal fibroblasts.
Discussion
The main novel findings of this study are that alterations
to individual CpG site methylation occur with COPD
status in lung cells, that dysfunction is more strongly
a b
c d
Fig. 3 Expression of genes associated with differentially methylated DNA regions. a TMEM44 expression in airway fibroblasts isolated from
individuals with and without COPD. b NXN expression in parenchymal fibroblasts isolated from individuals with and without COPD. c HLX
expression in parenchymal fibroblasts isolated from individuals with and without COPD. d SPON2 expression in parenchymal fibroblasts isolated
from individuals with and without COPD. **p < 0.01 compared with non-COPD control by unpaired t test, n = 15 non-COPD, n = 29 COPD
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associated with cell function (gene expression) in paren-
chymal fibroblasts than airway fibroblasts and that vari-
ability in DNA methylation may represent a stronger
analytical method to identify aberrant DNA methylation
associated gene expression than differential methylation
in a heterogeneous disease like COPD.
DNA methylation is considered to be an important
biological mechanism, which integrates genetic and en-
vironmental risk factors contributing to COPD patho-
genesis. DNA methylation is aberrant in the blood and
whole lung tissue DNA isolated from individuals with
COPD; however, these mixed cell samples, and with re-
gard to blood separation from the site of disease, com-
plicate defining molecular mechanisms underlying
COPD pathogenesis. Fibroblasts are critical to the de-
position of the physiological extracellular matrix (ECM)
and are considered to contribute to pathological ECM
scar tissue deposition in many obstructive airway dis-
eases including COPD. Fibroblasts reside within the lung
parenchyma and airways, and it is becoming increasingly
clear that these two locations define a distinct phenotype
of fibroblast that likely contributes differentially to lung
disease pathogenesis. In this paper, we use purified pop-
ulations of the airway and parenchymal fibroblasts from
individuals with and without COPD to identify disease-
associated, cell type-specific alterations to DNA
methylation.
We have considered whether any technical issues may
have affected our results. Our study was performed on
human airway and parenchymal fibroblasts, expanded in
vitro to passage 4 (except a single airway non-COPD
donor that was collected at passage 3). This provides the
benefit of a single cell type population for DNA methy-
lation analysis, which we know to be highly sensitive to
a b
c d
e f
Fig. 4 CpG methylation is differentially variable in parenchymal fibroblasts isolated from donors with COPD versus non-COPD. DNA methylation
array data for five CpGs identified as differentially variable in association with COPD status. a cg11475555 within 200 bp of the TRPV3 gene
transcription start site. b cg02065151 within 200 bp of the OAT gene transcription start site. c cg24753760. d cg16009558. e cg06247406 all within
200 bp of the GRIK2 gene transcription start site. f Pyrosequencing validation of cg16009559
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mixed cell populations. By using cells at the same pas-
sage, grown under the same conditions, it is unlikely
that the differences in DNA methylation and gene ex-
pression are due to cell culture effects. Furthermore, the
cells used in the study were collected from four different
sites to minimize isolation and culture technique effects.
Secondly performing the Illumina Infinium Human-
Methylation450 BeadChip array on bisulfite DNA does
not allow 5-methylcytosine to be distinguished from 5-
hydroxymethylcytosine. 5-Hydroxymethylcytosine is an oxi-
dized version of 5-methylcytosine produced by Ten-eleven
translocation (TET) enzymes as an intermediate base dur-
ing DNA demethylation. 5-Hydroxymethylcytosine is asso-
ciated with gene transcription and gene translation but via
potentially different mechanisms to 5-methylcytosine.
Further investigation of the mechanisms by which DNA
methylation regulates gene expression in the targets iden-
tified here is warranted and should include Tet-assisted
bisulfite pyrosequencing to distinguish between 5-
methylcytosine and 5-hydroxymethylcytosine. Finally, the
Illumina Infinium HumanMethylation450 BeadChip array,
while covering a valid representation of the genome, is not
truly genome-wide, and an analysis using bisulfite sequen-
cing or the more recently released Illumina EPIC array
may highlight further modifications to fibroblast DNA
methylation in association with COPD status.
Our initial linear modeling approaches did not identify
any individual differentially methylated CpG sites associ-
ated with COPD, potentially due to the large number of
features and low sample number, despite the current study
being the largest to date of purified cell types in COPD.
There are data reduction techniques that we could have
used, for example, selecting CpG sites within close (200/
1500 bp) proximity to transcription start sites, as these are
considered more likely to drive transcriptional changes.
However, a secondary part of this study was to also under-
stand how different types of DNA methylation, for ex-
ample, promoter versus gene body, affected steady-state
gene expression. For this reason, we chose to undertake
regional analysis using the R package DMRcate, consider-
ing that while individual site differences may be small, if
they are persistent across a region, the power to detect
them will be greater. The regional analysis did identify
regions of DNA differentially methylated between cells
isolated from individuals with and without COPD. Fur-
thermore, the location of these regions differed between
airway and parenchymal fibroblasts, confirming that dif-
ferent molecular mechanisms are induced in these two
cell types in association with COPD.
To assess the likelihood of statistically significant dif-
ferentially methylated DNA regions having downstream
biological effects, the absolute difference between the
means of the β values of the COPD and non-COPD
were calculated for each CpG within a region and
a
b
c
Fig. 5 Variable CpG methylation in parenchymal fibroblasts from
COPD donors is associated with differential gene expression. Gene
expression data generated by qPCR for the three genes associated
with variable CpG site methylation in parenchymal fibroblasts from
COPD donors. a TRPV3. b OAT. c GRIK2. *p < 0.05, **p < 0.01
compared with non-COPD control by Welch’s t test, n = 15 non-COPD,
n = 29 COPD
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referred to as the delta beta (Δβ). We considered a max-
imum difference in methylation of greater than 20%, that
is, at least one CpG site within the designated region
must have had a mean difference in methylation be-
tween samples from COPD and non-COPD donors of
greater than 20% (Δβ = 0.2), to be of biological interest.
After this filtering step, 45 regions remained of interest
in the airway fibroblasts, while only 3 remained for par-
enchymal fibroblasts. This suggested that airway fibro-
blasts are likely predisposed to larger alterations in DNA
methylation than parenchymal fibroblasts and therefore
that they may contribute to a greater extent to COPD
pathogenesis than previously considered. However, to
understand the biological significance of these DNA
methylation differences in greater detail, it was import-
ant to establish whether DNA methylation changes were
altering gene expression. We assessed gene expression
for all three parenchymal fibroblast regions and the five
regions from airway fibroblasts with the largest max-
imum difference in DNA methylation between non-
COPD and COPD samples. None of the airway fibro-
blast regions was associated with a difference in steady-
state gene expression, while two of the three parenchy-
mal regions did coincide with a significant difference in
gene expression. This highlights the necessity for inte-
grating DNA methylation and gene expression data to
confer biological importance. However, it does not
exclude that the differences in DNA methylation in the
airway fibroblasts may affect gene expression at regions
we did not assess by qPCR or in response to, for ex-
ample, lung/cell exposure to environmental COPD risk
factors (cigarette smoke/air pollution), and this warrants
c
e
d
a b
Fig. 6 GRIK2 CpG site methylation correlates with gene expression. Correlations between gene expression levels and DNA methylation (here
represented as M values, the log transformation of β values which are more statistically robust) for the three differentially variable CpG sites/
genes. a OAT. b TRPV3. c–e GRIK2. R2 values and p values are shown within the plots
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further investigation. Of interest, although one of the
significant parenchymal fibroblast regions was within
1500 bp of the transcription start site for SPON2, the re-
gion for HLX, which also showed a significant difference
in gene expression, is located within the gene body, em-
phasizing that location within the gene also does not ne-
cessarily confer effect at the gene expression level. We
isolated DNA and RNA simultaneously from the same
samples, a valuable resource, and a limitation of this
study is that we analyzed our RNA by targeted qPCR ra-
ther than genome-wide microarray or sequencing, which
would have been interesting to gain more information
regarding the association between gene expression and
DNA methylation.
Evidence for a greater dysfunction in DNA methyla-
tion regulated gene expression in parenchymal rather
than airway fibroblasts was further strengthened by a
secondary analysis of DNA methylation variability that
has previously been validated in other diseases [32, 33].
Identifying differentially methylated CpG sites compares
the mean level of DNA methylation between cases and
control while assessment of differential variability
(DVPs) essentially identifies individual sites displaying
“epigenetic outliers” in heterogeneous populations. The
current analysis did not identify any DVPs in airway fi-
broblasts but did identify 359 DVPs in parenchymal fi-
broblasts. As genome-wide gene expression was not
available for these samples to allow full integration to
DNA methylation data, we used a filtering process to
identify those CpG sites we hypothesized to be the most
likely to identify differential disease-associated gene ex-
pression (gene annotated, greater variability in COPD
than non-COPD, stable variation in non-COPD and lar-
gest variation in COPD, within 200 bp of a transcription
start site) and assessed the expression of the identified
genes by qPCR. The five sites that remained associated
with three different genes, two of which showed a sig-
nificant difference in expression between samples from
COPD and non-COPD donors (OAT and GRIK2) and a
third that displayed a strong trend (p = 0.0618) toward
differential expression (TRPV3). The higher success rate
of identifying differences in DNA methylation associated
with differential gene expression by variation analysis
than absolute differential analysis suggests that differen-
tial variation analysis may be a preferable method for
identifying DNA methylation regulated alterations in
gene expression associated with heterogeneous diseases
like COPD. However, we acknowledge that a full integra-
tion of genome-wide DNA methylation and gene expres-
sion data and permutation testing is required to
definitively prove this finding.
The largest difference in gene expression was seen for
GRIK2 with some donors displaying a greater than 80-fold
increase in expression compared to non-COPD donors.
GRIK2 expression also directly correlated with DNA
methylation levels in matched donor samples, indicating
that DNA methylation is tightly associated with GRIK2
gene expression. The direct relationship between both
GRIK2 and OAT expression and DNA methylation was
surprising, that is, for both OAT and GRIK2, DNA methy-
lation was higher in samples from COPD donors than
non-COPD donors, a phenomenon at gene promoters
that is normally associated with gene repression. Despite
this, qPCR data showed increased expression of both OAT
and GRIK2 in samples from COPD donors. Again, this
highlights that although general trends have been identi-
fied for the regulation of gene expression by DNA methy-
lation, the more studies that are performed, the more
exceptions to those trends arise and the more important it
is to look at DNA methylation in context with gene ex-
pression data rather than as an indicator of gene expres-
sion. Furthermore, future studies are warranted to
understand the mechanisms that mediate the relationship
between DNA methylation and gene expression. In
addition to differences in 5-methylcytosine and 5-
hydroxymethylcytosine ratios mentioned above, these
could include associations with methyl-DNA binding pro-
teins, modifications to histone tails, and the ability to re-
cruit specific transcription factors. This is likely to not
only be DNA region specific but also cell type and disease
context specific, and regimens to include these mechanis-
tic studies should be included in future studies of DNA
methylation in COPD.
GRIK2 belongs to the kainate family of glutamate re-
ceptors, and a small nucleotide polymorphism
(rs6570989) in GRIK2 has been associated with a status
of “current smoker” [34]. Our parenchymal fibroblast
cohort was matched for smoking pack-years but did in-
clude a mixture of current, ex-, and non-smokers, and
we were therefore interested in whether the variability in
DNA methylation was driven by smoking history. How-
ever, neither GRIK2 DNA methylation levels nor gene
expression levels correlated with pack-years (Add-
itional file 4: Figure S2a and b) or smoking status (Add-
itional file 4: Figure S2c and d). We also assessed GRIK2
single nucleotide polymorphisms (SNPs) in the donors
and the T allele SNP associated with current smoking
was only identified in a single non-COPD donor, to-
gether suggesting that COPD status rather smoking sta-
tus and genotype are driving the observed association
between GRIK2 DNA methylation and gene expression.
Conclusions
To conclude, we show that differences in DNA methyla-
tion are associated with COPD status and that these al-
terations can be associated with differences in functional
gene expression for specific genes. Differences in DNA
methylation profiles differ between airway and parenchymal
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fibroblasts suggesting that DNA methylation contributes
differently to disease pathology in these two distinct tissue
types with different functions within the lung. The associ-
ation between gene expression and DNA methylation was
complex and not predictable by the traditional dogma of
DNA methylation regulated gene expression. Finally, asses-
sing differentially variable DNA methylation may be a bet-
ter approach to identifying aberrant DNA methylation
regulated gene expression in heterogeneous diseases such
as COPD.
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